Patents by Inventor Lawrence S. Lamb

Lawrence S. Lamb has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190183930
    Abstract: The present disclosure provides methods of hematopoietic stem cell transplantation (HSCT). In particular, the present disclosure provides a method of HSCT using a combination of an in-vivo T-cell depletion method, with an ex-vivo method of ?? T cell expansion and ?? T cell depletion. The in-vivo T-cell depletion method depletes (in-vivo) the alloreactive T cells that would otherwise increase the risk of GvHD.
    Type: Application
    Filed: August 25, 2016
    Publication date: June 20, 2019
    Inventors: Lawrence S LAMB, Shin MINEISHI, Ayman SAAD
  • Patent number: 10322145
    Abstract: The present disclosure is generally related to methods for combining chemotherapy and immunotherapy for the treatment of a cancer. The methods also relate to generating a drug-resistant cytotoxic immune cell line and uses thereof in conjunction with cytotoxic drugs.
    Type: Grant
    Filed: May 21, 2014
    Date of Patent: June 18, 2019
    Assignees: Emory University, The UAB Research Foundation, Children's Healthcare of Atlanta, Inc.
    Inventors: Harold Trent Spencer, Anindya Dasgupta, Lawrence S. Lamb
  • Publication number: 20190175653
    Abstract: The present disclosure is generally related to methods for combining chemotherapy and immunotherapy for the treatment of a cancer.
    Type: Application
    Filed: February 22, 2019
    Publication date: June 13, 2019
    Applicants: Emory University, The UAB Research Foundation
    Inventors: Harold Trent Spencer, Anindya Dasgupta, Lawrence S. Lamb
  • Publication number: 20180250337
    Abstract: The present disclosure provides novel cell compositions engineered to express at least a chimeric antigen receptor and a survival factor. Methods of using such cell compositions are also described.
    Type: Application
    Filed: September 6, 2016
    Publication date: September 6, 2018
    Applicants: The UAB Research Foundation, Emory University, Children's Healthcare of Atlanta, Inc.
    Inventors: Lawrence S. Lamb, H. Trent Spencer, G. Yancey Gillespie
  • Publication number: 20150017137
    Abstract: The present disclosure is generally related to methods for combining chemotherapy and immunotherapy for the treatment of a cancer.
    Type: Application
    Filed: May 21, 2014
    Publication date: January 15, 2015
    Inventors: Harold Trent Spencer, Anindya Dasgupta, Lawrence S. Lamb
  • Publication number: 20120258532
    Abstract: The present disclosure is generally related to methods for combining chemotherapy and immunotherapy for the treatment of a cancer. The methods also relate to generating a drug-resistant cytotoxic immune cell line and uses thereof in conjunction with cytotoxic drugs.
    Type: Application
    Filed: October 29, 2010
    Publication date: October 11, 2012
    Inventors: H. Trent Spencer, Anindya Dasgupta, Lawrence S. Lamb
  • Patent number: 7078034
    Abstract: Patients who develop increased numbers of ??+ cytotoxic T lymphocytes 2–6 months after allogeneic bone marrow transplantation are less likely to relapse than those who do not. The ??+ T cells isolated from blood of patients with increased ??+ T cells are CD3+CD4?CD8?CD57+, cytolytic to K562 cells, and express the V?1 T cell receptor phenotype. Similar ??+ T cells can be generated in vitro by culture of donor mononuclear cells which are enriched for ??+ T cells by immunomagnetic depletion of depleted of CD4+ and CD8+ cells. This ??-enriched cell preparation was cultured on a combination of immobilized pan-? monoclonal antibody and irradiated recipient B cell leukemia. After four weeks, the cultures were almost exclusively V?1+CD3+CD4?CD8? cells that co-expressed activation-associated antigens CD69, CD25, and HLA-DR.
    Type: Grant
    Filed: June 12, 2001
    Date of Patent: July 18, 2006
    Assignee: Palmetto Health Alliance
    Inventor: Lawrence S. Lamb, Jr.
  • Publication number: 20030223998
    Abstract: The present invention provides novel methods and compositions for the treatment of cancer, and in particular for acute lymphoblastic leukemia (ALL). The present invention also relates to the use of &ggr;&dgr;+ T cells to identify and respond to a specific antigen expressed by ALL, thereby enabling the targeted treatment of ALL. Diagnostic methods and kits for the detection and monitoring of cancer are also provided.
    Type: Application
    Filed: February 27, 2003
    Publication date: December 4, 2003
    Inventors: Lawrence S. Lamb, Philip Musk
  • Publication number: 20010051151
    Abstract: Patients who develop increased numbers of &ggr;&dgr;+ cytotoxic T lymphocytes 2-6 months after allogeneic bone marrow transplantation are less likely to relapse than those who do not. The &ggr;&dgr;+ T cells isolated from blood of patients with increased &ggr;&dgr;+ T cells are CD3+CD4−CD8−CD57+, cytolytic to K562 cells, and express the V&dgr;1 T cell receptor phenotype. Similar &ggr;&dgr;+ T cells can be generated in vitro by culture of donor mononuclear cells which are enriched for &ggr;&dgr;+ T cells by immunomagnetic depletion of depleted of CD4+ and CD8+ cells. This &ggr;&dgr;-enriched cell preparation was cultured on a combination of immobilized pan-&dgr; monoclonal antibody and irradiated recipient B cell leukemia. After four weeks, the cultures were almost exclusively V&dgr;1+ CD3+CD4−CD8− cells that co-expressed activation-associated antigens CD69, CD25, and HLA-DR.
    Type: Application
    Filed: June 12, 2001
    Publication date: December 13, 2001
    Inventor: Lawrence S. Lamb